PNC Financial Services Group Inc. Acquires Shares of 19,789 Pulse Biosciences, Inc. (NASDAQ:PLSE)

PNC Financial Services Group Inc. acquired a new stake in Pulse Biosciences, Inc. (NASDAQ:PLSE) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 19,789 shares of the company’s stock, valued at approximately $242,000.

Pulse Biosciences Stock Down 3.2 %

NASDAQ PLSE opened at $10.83 on Tuesday. Pulse Biosciences, Inc. has a 52 week low of $3.78 and a 52 week high of $14.96. The business’s fifty day simple moving average is $10.14 and its 200-day simple moving average is $9.56. The firm has a market cap of $598.03 million, a PE ratio of -13.37 and a beta of 1.75.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.17) EPS for the quarter.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a report on Thursday, June 27th.

Insider Transactions at Pulse Biosciences

In related news, CEO Burke Thomas Barrett purchased 10,000 shares of Pulse Biosciences stock in a transaction dated Monday, May 20th. The shares were acquired at an average price of $8.56 per share, for a total transaction of $85,600.00. Following the acquisition, the chief executive officer now directly owns 10,000 shares in the company, valued at $85,600. The purchase was disclosed in a filing with the SEC, which is available through this link. Insiders own 71.50% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.